Skip to main content
BATM Advanced Communications Ltd. logo

BATM Advanced Communications Ltd. — Investor Relations & Filings

Ticker · BVC ISIN · IL0010849045 LEI · 213800FLQUB9J289RU66 TA Telecommunications, computer programming, consultancy, computing infrastructure, and other information service activities
Open in API
Filings indexed 947 across all filing types
Latest filing 2024-12-19 Regulatory Filings
Country IL Israel
Listing TA BVC

About BATM Advanced Communications Ltd.

https://www.batm.com/

BATM Advanced Communications Ltd. is a technology company specializing in the development of networking, cybersecurity, and bio-medical systems. The company operates through two main divisions. The Networking & Cyber division provides advanced network infrastructure solutions for service providers, enabling scalable connectivity from the core to the edge. This division also offers quantum encryption technologies to secure mission-critical data-in-transit. The Bio-Medical division develops and markets In Vitro Diagnostic (IVD) systems, including innovative PCR instruments and high-quality reagents, designed for the rapid and accurate detection and management of diseases.

Recent filings

Filing Released Lang Actions
New Tier 1 Customer for Edgility in Mexico
Regulatory Filings Classification · 100% confidence The document is a press release dated December 19, 2024, announcing a new customer win for BATM's Edgility platform by Axtel in Mexico. It details a business development and partnership, including quotes from the CEO and contact information for enquiries. This type of announcement, which is a specific operational or business update that is not a full financial report (10-K, IR), earnings release (ER), or management discussion (MDA), fits best under the general category for regulatory announcements that do not have a more specific code. Since it is a formal announcement of a significant business event, and it is not a dividend, capital change, director dealing, or M&A activity, the most appropriate general category is Regulatory Filings (RNS), which serves as a fallback for miscellaneous official announcements.
2024-12-19 English
New Tier 1 Customer for Edgility in Mexico
Report Publication Announcement Classification · 98% confidence The document is very short (1891 characters) and explicitly states that a report is attached: "Attached hereto is a report on... *Customer_in_Mexico_for_Edgility_isa.pdf*". It also mentions the scheduled publication date and references the Israel Securities Authority and Tel Aviv Stock Exchange, indicating a regulatory filing context. Because the document itself is merely an announcement stating that a report is attached or published, rather than containing the full content of a specific report type (like 10-K, IR, or ER), it fits the definition of a Report Publication Announcement (RPA).
2024-12-19 English
NATlab commences pre-clinical validation
Regulatory Filings Classification · 100% confidence The document begins with an 'RNS Number' and is dated 11 December 2024. It announces a key operational milestone regarding the NATlab platform commencing pre-clinical validation. The text concludes with contact information and a footer explicitly stating, "This information is provided by RNS, the news service of the London Stock Exchange." This structure is characteristic of a general regulatory news service announcement, which is not a full financial report (like 10-K or IR) or a specific announcement like a dividend (DIV) or director dealing (DIRS). Since it is a general, immediate announcement distributed via the London Stock Exchange's news service (RNS), the most appropriate classification is Regulatory Filings (RNS), as it serves as the general regulatory announcement fallback.
2024-12-11 English
Key milestone achieved with commencement of NATlab pre-clinical validation
Regulatory Filings Classification · 100% confidence The document is a press release dated December 11, 2024, announcing a key operational milestone: the commencement of pre-clinical validation for the NATlab platform at a major Italian hospital. It details progress, trial results, grant funding, and includes quotes from the CEO. This type of announcement, focusing on specific operational or strategic updates rather than comprehensive periodic financial results (like a 10-K or IR), is characteristic of an Earnings Release (ER) or a general Regulatory Filing (RNS). Since it is an announcement of operational progress and not a formal financial report, and it doesn't fit the specific criteria for M&A (TAR), Capital (CAP), or Director Dealing (DIRS), it is best classified as an Earnings Release (ER) if it accompanies or precedes a reporting period, or RNS if it's purely operational news. Given the nature of the update (a key milestone achievement), it functions similarly to an Earnings Release highlighting positive developments, but since it is not explicitly labeled as Q3/Q4 results, the most appropriate general category for significant, non-standard operational news is often RNS, or ER if it's a standalone update. However, many companies use ER for significant operational updates outside of the formal quarterly filing structure. Given the content is a specific business update with a positive tone, it aligns closely with the function of an ER, which often includes operational highlights. Since it is not a full report, and it's a specific announcement, I will lean towards ER as it relates to business performance drivers, but RNS is a strong secondary candidate. Given the context of financial reporting databases, specific operational updates often fall under ER if they are material. I will classify it as ER, as it reports on a key development impacting future revenue potential.
2024-12-11 English
Key milestone achieved with commencement of NATlab pre-clinical validation
Report Publication Announcement Classification · 98% confidence The document is a very short filing (1903 characters) published via the MAGNA system, referencing the Israel Securities Authority (ISA) and the Tel Aviv Stock Exchange. The key phrase is: "Attached hereto is a report on *����� ������ ����-����� �� NATlab* *Commencement_of_NATlab_pre-clinical_validation_isa.pdf*". This structure—a brief announcement stating that a specific report (in this case, likely related to clinical validation or a specific event) is attached or published—fits the definition of a Report Publication Announcement (RPA) according to Rule 2 ("THE 'MENU VS MEAL' RULE"). It is announcing the release of a PDF document rather than being the full report itself.
2024-12-11 English
Block Listing Interim Review
Remuneration Information Classification · 99% confidence The document is identified by the 'RNS Number' and contains a 'BLOCK LISTING SIX MONTHLY RETURN' for the 'Global Share Incentive Plan (2021)' covering the period from June 1, 2024, to November 30, 2024. This is a specific regulatory filing related to the listing of shares, often required by listing authorities (like the LSE). Since it is a specific, recurring regulatory return that doesn't fit into the primary financial report categories (10-K, IR, ER), and it is clearly an official announcement distributed via RNS, it should be classified as a general Regulatory Filing (RNS). The document length is short (2193 chars), but the content is the filing itself, not an announcement *about* the filing, making RNS more appropriate than RPA.
2024-12-03 English

Browse filings by year

17 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.